TheranosticTrials.org

Clinical Trial · NCT07475390

99mTc-1-thio-D-glucose SPECT/CT Versus 18F-Fluoroethyl-l-tyrosine PET/CT in Brain Tumor Imaging

Overview

An open-label, single-center study with 99mTc-1-thio-D-glucose single photon emission computed tomography / computed tomography (SPECT/CT) and 18F-fluoroethyl-l-tyrosine (18F-FET) positron emission tomography / computed tomography (PET/CT) in primary and recurrent glioma patients, where the primary endpoint of the study is to compare imaging properties of 99mTc-1-thio-D-glucose SPECT/CT and 18F-FET PET/CT of brain tumor Imaging.

Sponsor

Tomsk National Research Medical Center of the Russian Academy of Sciences

Phase

N/A

Contacts

Vladimir I Chernov, MD, Prof. (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT07475390

Drug / Compound

1-thio-D-glucose

Isotope(s):
Target(s):
  • Glucose Transport
Ligand Class: Small Molecules

FET

Isotope(s):
Target(s):
  • Amino Acid Transport
Ligand Class: Small Molecules

Eligibility

Inclusion

  • Hemoglobin: \> 80 g/L
  • Platelets: \> 50.0 x 109/L
  • Diagnosis of primary and recurrent glioma;
  • Sequential injection of 99mTc-1-thio-D-glucose and 18F-FET in the interval of 14 days in each patient;

Exclusion

  • Second, non-brain malignancy;